May 26, 2020
Mitsubishi Tanabe Pharma said on May 25 that its DPP-4 inhibitor Tenelia (teneligliptin) was approved in Thailand for the treatment of type 2 diabetes. The drug will be marketed by the company’s local subsidiary, Mitsubishi Tanabe Pharma (Thailand), under the...read more